CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

CRISPR Therapeutics AGNASDAQ: CRSP

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares of 96.74M shares rose 6.0% year over year, behind the +8.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +5.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +6.0% toward the trailing-twelve-month pace of +8.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
96.74M+0.2% QoQ
Last fiscal yearDec 2025
89.93M+6.6% YoY
LTMSep 2026
94.81M+8.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.0%——
1 year+6.6%——
3-year CAGR+5.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
89.93M USD
Year-over-year change
+6.6%
4-year CAGR
+4.3%

Weighted Avg Shares vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 weighted avg shares of 94.81M shares is the 3rd highest of the 7 companies compared; the peer median is 73.33M shares.
  • Its year-over-year change of +8.4% is the 5th highest of 7, against a peer median of +9.3%.
  • Over three fiscal years its annual growth of +5.0% compares with a peer median of +10.9%.
CRSP Competitors Peer median
Weighted Avg Shares for CRSP and competitors
Company Period LTM YoY 3-year CAGR
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.26M +16.4%+12.2%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 202656.38M +7.5%+9.8%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
Peer median (excluding CRSP) 73.33M+9.3%+10.9%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue913.08M436K370M35M3.51M
Cost of Revenue101.18M110.25M130.25M110.25M232.96M
Gross Profit811.9M(109.81M)239.75M(75.25M)(229.45M)
Gross Margin88.9%-25186.7%64.8%-215.0%-6537.0%
Research & Development340.57M461.65M387.33M320.65M265.33M
Selling, General & Admin99.69M102.46M76.16M72.98M73.54M
Operating Expenses438.38M563.35M462.29M391.32M338.87M
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
EBITDA397.48M(626.33M)(130.89M)(343.41M)(558.49M)
EBITDA Margin43.5%-143653.2%-35.4%-981.2%-15911.3%
Operating Income373.53M(673.16M)(222.54M)(466.57M)(568.32M)
Operating Margin40.9%-154394.7%-60.1%-1333.0%-16191.4%
Interest Income00000
Interest Expense00000
Other Income / Expenses6M22.66M71.82M103.9M(9.65M)
Income Before Tax379.53M(650.5M)(150.72M)(362.67M)(577.97M)
Pre-Tax Margin41.6%-149197.2%-40.7%-1036.2%-16466.2%
Income Tax Expense1.87M(325K)2.89M3.59M3.63M
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Net Margin41.4%-149122.7%-41.5%-1046.4%-16569.8%
EPS (Basic)4.97(8.36)(1.94)(4.34)(6.47)
EPS (Diluted)4.70(8.36)(1.94)(4.34)(6.47)
Weighted Avg Shares75.95M77.75M79.22M84.36M89.93M
Weighted Avg Shares (Diluted)80.39M77.75M79.22M84.36M89.93M

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.